Category: Cancer Pharmacology
-
DFMO: The Pill Designed to Help Keep High-Risk Neuroblastoma From Coming Back
In December 2023, the FDA approved eflornithine, also called DFMO or Iwilfin, to help reduce the risk that high-risk neuroblastoma comes back after intensive treatment. The science centers on polyamines, small molecules that some MYCN-driven tumors rely on to keep growing.
-
Can weight-loss drugs lower cancer risk? What the GLP-1 boom is really telling us
Written and edited by Abel B. Daartey, PharmD Key Takeaways GLP-1 medicines have moved very quickly from diabetes clinics into the center of public conversation. Many people know them by brand names such as Ozempic, Wegovy, Mounjaro, and Zepbound. At first, the main story was blood sugar. Then it became weight loss. Now, a more…
-
Why Are More Young People Getting Colon Cancer?
Early-onset colorectal cancer is rising in adults younger than 50. The causes are probably mixed: diet, metabolism, gut bacteria, alcohol, sedentary life, early-life exposures, and delayed recognition of symptoms.
-
Catch It Early: The Science and Limits of Cancer Screening
Cancer screening saves lives when used for the right cancers and the right people. But it also has limits, including false positives, overdiagnosis, and the need for careful follow-up.
BreathPharma 